Skip to content

Developing a reliable and validated screening assay for hepatitis B associated liver cancers.

Development of a miRNA based screening assay for Hepatitis B virus (HBV) associated Hepatocellular Carcinoma (HCC).

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2020/09/027891
Enrollment
120
Registered
2020-09-18
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C220- Liver cell carcinoma

Interventions

Intervention1: NIL: NIL

Sponsors

Manipal Academy of Higher Education
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Chronic hepatitis B positive (HBsAg/Anti HBc IgG) with no radiological evidence of liver fibrosis. Chronic hepatitis B positive liver cirrhosis cases diagnosed with upper GI endoscopic data of esophageal/gastric varices, portal hypertension or radiological features. Anti-HBc IgG positive Hepatocellular carcinoma cases will be identified by ultrasonography or with or without histological evidence. Anti-HBc IgG negative hepatocellular carcinoma cases diagnosed by ultrasonography with or without histological evidence. Normal healthy controls.

Exclusion criteria

Exclusion criteria: Patients with other liver diseases, pregnant women, individuals below 18 years of age, co-infection with HIV, Hepatitis C virus (HCV), serious concurrent medical illnesses like malignancy and uncontrolled diabetes mellitus will be excluded.

Design outcomes

Primary

MeasureTime frame
Our study will become a platform for developing highly specific multiple microRNA based screening assay for other cancers like HPV associated oropharyngeal and anal cancers for which there does not exist a recommended screening tool.Timepoint: 2 years

Secondary

MeasureTime frame
Tumour specific miRNA targets will facilitate drug development leading to precision medicine with minimal side effectsTimepoint: 2 years

Countries

India

Contacts

Public ContactDr Shiran Shetty

Kasturba Medical College

drshiran@gmail.com8861920517

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026